In this article, we deep dive into the 5 top-performing stocks on Monday. For a deeper discussion and an extended list, please see 10 Stocks Paying Off Big Time.

5. Biohaven Ltd. (NYSE:BHVN)

Biohaven saw its share prices climb by 14.22 percent on Monday to finish at $15.50 apiece, as investors resumed buying positions ahead of the initiation of two clinical studies by the end of the month.

Based on its key milestone calendar, Biohaven Ltd. (NYSE:BHVN) is set to initiate clinical studies for its BHV-1510 for advanced or metastatic epithelial tumors, as well as the BHV-1530 for urothelial cancer and other tumors, by the end of the month.

It is also planning to begin pivotal studies for BHV-1400 for the treatment of IgAN, or Berger disease, as well as BHV-1300 for Graves’ disease, in the middle of the year.

Biohaven Ltd. (NYSE:BHVN) is a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology.

In the first quarter of the year, it was able to slash its net losses by 41 percent to $130.5 million from $221.7 million in the same period last year. It has yet to generate revenues as of the period.

4. United Microelectronics Corp. (NYSE:UMC)

United Microelectronics saw its share prices jump to a new all-time high, as investors loaded portfolios following reports that it is collaborating with Intel Corp. for the production of semiconductors.

In intra-day trading, the stock climbed to its highest price of $28.27 before paring gains to finish the session just up by 14.20 percent at $27.50 apiece.

An unverified report on the same day said that United Microelectronics Corp. (NYSE:UMC) is partnering with Intel Corp. anew for the development of advanced manufacturing process technologies.

The report added that the partnership would primarily focus on chips using 12nm and 3nm process nodes, with production expected to take place at Intel’s facility in Arizona.

United Microelectronics Corp. (NYSE:UMC), however, refused to issue a statement in relation to the buzz, saying that it “does not comment on unverified reports.”

If proven, the deal would mark a deepened collaboration between United Microelectronics Corp. (NYSE:UMC) and Intel, having already joined forces in 2024 for the development of a 12nm process platform.

Under their previous agreement, the two firms engaged in the development of a 12-nanometer semiconductor process platform to address high-growth markets such as mobile, communication infrastructure, and networking.

3. Super Micro Computer Inc. (NASDAQ:SMCI)

Super Micro rallied for a second day on Monday, jumping 15.66 percent to finish at $35.46 apiece, as investors loaded portfolios following the launch of a new blueprint for the development of next-generation AI and supercomputing data centers.

At the ongoing ISC 2026 conference in Hamburg, Germany, Super Micro Computer Inc. (NASDAQ:SMCI) unveiled its new blueprint, powered by Nvidia Corp.’s Vera Rubin NVL4 platform, and is designed for high-performance computing systems.

It said that the blueprint is based on Supermicro’s DCBBS, which provides the necessary compute, networking, advanced liquid cooling, power distribution, and site infrastructure, delivered by a team of Supermicro DCBBS experts to accelerate time-to-online for research institutions and supercomputing centers.

“Scientific discovery has always been driven by the tools available to researchers, and AI has become an essential part of the research process,” Super Micro Computer Inc. (NASDAQ:SMCI) President and CEO Charles Liang said.

“The institutions that accelerate infrastructure deployment will lead the next generation of breakthroughs. With our DCBBS Blueprints for NVIDIA Vera Rubin NVL4, research organizations can confidently deploy HPC and AI infrastructure at any scale, knowing that it is backed by Supermicro’s proven experience building some of the world’s largest liquid-cooled clusters,” he noted.

2. Apogee Therapeutics Inc. (NASDAQ:APGE)

Apogee Therapeutics soared to a fresh all-time high on Monday, as investors gobbled up shares following announcements that it is set to be acquired by pharmaceutical giant AbbVie Inc. at a 49 percent premium.

In a joint statement on the same day, the two firms said that they have officially inked a definitive agreement for their planned merger for a total of $10.9 billion.

Under the terms of the agreement, AbbVie will acquire all shares of Apogee Therapeutics Inc. (NASDAQ:APGE) at a price of $135.11 apiece, or a 49.5 percent premium over its closing price of $90.38 on Friday, or prior to the announcement.

Following the news, Apogee Therapeutics Inc. (NASDAQ:APGE) climbed to its highest price of $133 before trimming gains to finish the session up by 46.66 percent at $132.55 apiece.

AbbVie said that the acquisition forms part of its efforts to strengthen its portfolio in immunology, given Apogee Therapeutics Inc.’s (NASDAQ:APGE) diverse pipeline of assets focused on elevating the standard of care for patients with dermatologic, respiratory, and other related inflammatory and immunological diseases.

Subject to regulatory approvals, including shareholders, the transaction is expected to be completed in the third quarter of the year.

1. Definium Therapeutics Inc. (NASDAQ:DFTX)

Definium Therapeutics saw its share prices jump to a nearly five-year high on Monday, as investors positioned their portfolios after reporting strong results from the late-stage clinical trial of its therapy candidate for major depressive disorders (MDD).

In intra-day trading, the stock climbed to a record high of $39.16 before trimming gains to end the session just up by 49.80 percent at $36.67 apiece.

In an updated report during the day, Definium Therapeutics Inc. (NASDAQ:DFTX) said that the Least Squares Mean—a statistical method used to calculate the average improvement in depression symptom scores—stood at -13.3 for patients in the DT120 group, as compared with the -5.2 for patients in the placebo group, at week 6.

DT120 was able to achieve all key primary and secondary endpoints, demonstrating statistically significant and clinically meaningful improvement from baseline.

Definium Therapeutics Inc. (NASDAQ:DFTX) was also generally well-tolerated, with 99 percent of adverse effects only mild to moderate in severity, and were only transient and predominantly occurring on the day of dosing.

Importantly, no new safety signals were identified, including no increase in suicidal ideation or behavior. Discontinuations were also low and comparable between treatment groups.

“The Emerge topline results represent unprecedented and highly differentiated efficacy, demonstrating that a single dose of DT120 ODT can deliver rapid, robust, and durable relief in MDD,” Definium Therapeutics Inc. (NASDAQ:DFTX) CEO Rob Barrow said.

“Emerge (the study) marks a major milestone in our development program and strengthens our confidence in DT120 as a potential best-in-class treatment for mental health disorders. These findings could support a fundamentally new approach to treating MDD for patients and providers who continue to face the limitations of existing treatment options. We are deeply grateful to the patients and investigators who participated in this trial,” he noted.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge fund investor letters by entering your email below.